| Quarter | Action | Shares change | Est. value change | Δ Own | Shares held | Filing date |
|---|---|---|---|---|---|---|
| Q1 2026 | Reduced | −2.5M | −$60M | −74.9% | 845K | May 15, 2026 |
| Q4 2025 | Unchanged | – | – | – | 3.4M | Feb 17, 2026 |
| Q3 2025 | Added | +655K | +$13M | +24.2% | 3.4M | Nov 14, 2025 |
| Q2 2025 | Added | +558K | +$13M | +25.9% | 2.7M | Aug 14, 2025 |
| Q1 2025 | New | +2.2M | +$48M | – | 2.2M | May 15, 2025 |
Yes. As of Q1 2026, Terry Smith disclosed 845K shares of CPRX, worth $21M. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.
Terry Smith first disclosed a CPRX position in Q1 2025; every quarterly buy and sell since is in the table above. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.
The quarter-by-quarter table above shows each sale and reduction Terry Smith disclosed in CPRX. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.
Terry Smith disclosed 845K shares of CPRX as of Q1 2026. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.
Terry Smith's estimated average buy price for CPRX is $22.32, from quarter-average prices weighted by the shares added each quarter. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.
13F filings disclose quarter-end holdings, not trade dates or execution prices. These estimates use each covered quarter's average market price; the add average excludes the opening position and quarters without price data. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.